#AutoSCT - Twitter Hashtag

Laura Saavedra Salazar @Laura_SaavedraS

7 months ago

Our second e-poster number 2127 is about the results of a second #AutoSCT in a patient with R/R #MM

2

7

0

220

Satya Prakash Yadav @Satyayadav__

over 1 year ago

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT #MS #AutoSCT https://t.co/ZPmWKQjJ7d

0

5

1

2

240

Transplantation and Cellular Therapy Journal @ASTCT_Journal

almost 3 years ago

Patients with large b cell lymphoma and a high international prognostic index score of 4 to 5 experience poor outcomes with R-CHOP. Consolidative #autoSCT for high-risk #LBCL achieves 5-year disease-specific survival in 80% of recipients. Read more: https://t.co/pSokZPv0nL

ASTCT_Journal's tweet photo. Patients with large b cell lymphoma and a high international prognostic index score of 4 to 5 experience poor outcomes with R-CHOP. Consolidative #autoSCT for high-risk #LBCL achieves 5-year disease-specific survival in 80% of recipients. Read more: https://t.co/pSokZPv0nL https://t.co/h6rxfigNhu

0

18

2

4

8K

Transplantation and Cellular Therapy Journal @ASTCT_Journal

about 3 years ago

The authors of this article provide updates on their experiences with a TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) conditioning regimen for Hodgkin lymphoma and non-hodgkin lymphoma subtypes. Read more: https://t.co/wVTXKJs73o #Lymsm #autoSCT

ASTCT_Journal's tweet photo. The authors of this article provide updates on their experiences with a TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) conditioning regimen for Hodgkin lymphoma and non-hodgkin lymphoma subtypes. Read more: https://t.co/wVTXKJs73o #Lymsm #autoSCT https://t.co/LMig2Yx0Rr

0

17

5

3

2K

Transplantation and Cellular Therapy Journal @ASTCT_Journal

about 3 years ago

Patients diagnosed with r/r diffuse LBCL or high-grade B cell lymphoma may achieve prolonged survival following receipt of high-dose chemo/#autoSCT or CD19-directed #CARTcell therapy. Early results show CART19 as second-line therapy results in improved OS. https://t.co/leRHBkKSry

ASTCT_Journal's tweet photo. Patients diagnosed with r/r diffuse LBCL or high-grade B cell lymphoma may achieve prolonged survival following receipt of high-dose chemo/#autoSCT or CD19-directed #CARTcell therapy. Early results show CART19 as second-line therapy results in improved OS. https://t.co/leRHBkKSry https://t.co/VKWiPyaPmM

1

17

5

1

2K

Cristobal Frutos @chano_py

about 3 years ago

1 year post #AutoSCT for Systemic Sclerosis (#scleroderma) AutoSCT is a safe (and cheap) option in #LMIC settings Patient selection and timing of SCT is key with careful multidisciplinary evaluation (🫀, 🫁+ GI tract) @HematologiaIPS @bancodesangrepy @Romiglizt

chano_py's tweet photo. 1 year post #AutoSCT for Systemic Sclerosis (#scleroderma)
AutoSCT is a safe (and cheap) option in #LMIC settings
Patient selection and timing of SCT is key with careful multidisciplinary evaluation (🫀, 🫁+ GI tract)
@HematologiaIPS @bancodesangrepy @Romiglizt https://t.co/7htTd8gBtm

3

30

4

0

2K

ASTCT

@ASTCT

over 3 years ago

In one of the first real-world studies of next gen flow cytometry for MRD monitoring of #MM therapy, lenalidomide maintenance therapy & MRD status post #autoSCT were independent predictors of progression-free survival. https://t.co/2g9OHJRBpm @ufrj @MDPIOpenAccess

0

1

0

1K

Cristobal Frutos @chano_py

over 3 years ago

Jesus San Miguel on proposed algorithm of treatment for patients with #MM at #Gammi @SAHematologia #AutoSCT I see you there.. this is 2023 treatment algorithm

chano_py's tweet photo. Jesus San Miguel on proposed algorithm of treatment for patients with #MM at #Gammi @SAHematologia
#AutoSCT I see you there.. this is 2023 treatment algorithm https://t.co/cpjfwRfNn1

1

5

1

0

501

Herbert Wertheim Cancer Institute Research

@MiamiCancerInst

over 3 years ago

Excited to have Dr. @GunjanLShah (@MSKCancerCenter) present on Auto SCT vs. CAR T and highlight the benefits and limitations of each therapy and their applicability to different patient populations. #MyelomaTreatment #CAR_T #AutoSCT #MCIImmunotherapySummit

0

3

0

82

Transplantation and Cellular Therapy Journal @ASTCT_Journal

over 3 years ago

This article found that Hospital-at-Home programs is a feasible strategy after autologous stem cell transplantation: https://t.co/menUXbzIzG #stemcell #autoSCT #HospitalatHome

ASTCT_Journal's tweet photo. This article found that Hospital-at-Home programs is a feasible strategy after autologous stem cell transplantation: https://t.co/menUXbzIzG #stemcell #autoSCT #HospitalatHome https://t.co/x8kdp9us42

1

26

9

4

3K

Jeff Szer @marrow

almost 4 years ago

Gerard Illerhaus presenting European study looking at lower dose chemoimmunotherapy in primary CNS lymphoma compared to #autoSCT. High dose chemotherapy improved overall survival and PFS. #LBA #ASH22

marrow's tweet photo. Gerard Illerhaus presenting European study looking at lower dose chemoimmunotherapy in primary CNS lymphoma compared to #autoSCT. High dose chemotherapy improved overall survival and PFS. #LBA #ASH22 https://t.co/D494FBZsWd

0

2

0

Cristobal Frutos @chano_py

almost 4 years ago · New Orleans

Can we omit #AutoSCT in relapsed Hodgkin Lymphoma in 2nd line? Im listening #ASH22

2

8

2

0

Felipe Peña-Muñoz @HematoRules

about 4 years ago · Barcelona

#CARTcells vs #AutoSCT for #DLBCL 2L? Still working on this! Chemo resistance and early relapse (<12 months) as deal breakers! @albertomussetti @HHospitalet #ITC22 @TheEBMT @TheEBMT_CTIWP @TheEBMT_Trainee

HematoRules's tweet photo. #CARTcells vs #AutoSCT for #DLBCL 2L? Still working on this!

Chemo resistance and early relapse (<12 months) as deal breakers!

@albertomussetti @HHospitalet #ITC22 @TheEBMT @TheEBMT_CTIWP @TheEBMT_Trainee https://t.co/P7Gb0vX392

0

4

1

0

Cristobal Frutos @chano_py

over 4 years ago

Biologic basis of the impact of AutoSCT on Multiple Myeloma in cuadruplet treatment era.. MRD by NGS (sigh 😖).. "At this time #AutoSCT should remain an integral part for #NDMM fit patients" #Tandem22 @gelamm_latam

1

9

3

0

Cristobal Frutos @chano_py

almost 5 years ago

@NicoGagelmann @GomezDLeonMD What if I told you not even #AutoSCT can be given to everyone in need in #LMIC. Hope one day as much effort (& spotlight) is given to reaching people as is given to novel treatments. Not saying innovation isnt important. But reaching everyone in need should be as important #ASH21

chano_py's tweet photo. @NicoGagelmann @GomezDLeonMD What if I told you not even #AutoSCT can be given to everyone in need in #LMIC. Hope one day as much effort (& spotlight) is given to reaching people as is given to novel treatments. Not saying innovation isnt important. But reaching everyone in need should be as important #ASH21 https://t.co/HUes55R09B

0

3

0

Taha A, MD, MBA @Taha_CancerDoc

over 5 years ago

Without OS benefit then #autoSCT will remain a viable option for patients and it’s on us to figure out how to sequence these therapies to get the best possible outcomes for our patients. Thanks @MediHumdani for your usual informative analysis. #lymsm #bmtsm #CARtcell #lymphoma

Mehdi Hamadani, MD @MediHumdani

over 5 years ago

Do BMS/Kite results #ChangePractice? Beware of designs to help industry Auto works in CR/PR. These studies randomized before that (#PARMA) So if they improve OS = They r practice changing Even if they improved "as treated" PFS = OK But EFS = Not so fast https://t.co/zRKuRYvyGu

4

62

15

14

0

1

2

0

HemaSphere Journal (prelim IF = 11.3)

@Hemasphere_EHA

over 5 years ago

For pts with #MCL, prognosis after relapse is poor & #StandardOfCare lacking. What are the prognostic impacts of #POD24 + biomarkers independent of POD24, and which chemo regimens are superior for high-risk pts at 1st POD? 👉https://t.co/1NUdYMCfz4 #ProgressionOfDisease #autoSCT

Hemasphere_EHA's tweet photo. For pts with #MCL, prognosis after relapse is poor & #StandardOfCare lacking. What are the prognostic impacts of #POD24 + biomarkers independent of POD24, and which chemo regimens are superior for high-risk pts at 1st POD? 👉https://t.co/1NUdYMCfz4
#ProgressionOfDisease #autoSCT https://t.co/pB0FBz5yC7

0

2

0

Mateo Mejia @mmejia91

almost 6 years ago

Likewise, health insurance can have a profound impact in access to novel agents and #AutoSCT as well. Makhani et al (https://t.co/Z1e29EVOyE) described how insurance status can affect outcomes in #mmsm, representing one of the potential barriers for these therapies. 4/

1

2

0

Cristobal Frutos @chano_py

almost 6 years ago · Asuncion

E-CEL (engineered endothelial cells) #AB205 derived from allogeneic umbilical endothelial cells when used in the #AutoSCT setting appears to reduce Oral/GI Grade 3-4 AE for lymphoma. While mucositis is expected and to a degree not worrisome it does impact #QoL greatly #ASH20

chano_py's tweet photo. E-CEL (engineered endothelial cells) #AB205 derived from allogeneic umbilical endothelial cells when used in the #AutoSCT setting appears to reduce Oral/GI Grade 3-4 AE for lymphoma. While mucositis is expected and to a degree not worrisome it does impact #QoL greatly #ASH20 https://t.co/EPxsbkuxrb

0

2

0

Cristobal Frutos @chano_py

almost 6 years ago · Asuncion

Me: You're still recovering from the Transplant so take it easy ok but exercise always helps speed up recovery Patient: Hold my beer Day +28 post #AutoSCT

chano_py's tweet photo. Me: You're still recovering from the Transplant so take it easy ok but exercise always helps speed up recovery
Patient: Hold my beer
Day +28 post #AutoSCT https://t.co/kVTogRBoJq

0

13

0

Top Tweets for #AutoSCT

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users